Efficacy of Calcium Hydroxyapatite in Vocal Fold Augmentation for Unilateral Vocal Fold Paralysis in Asian
- Author:
Doh Young LEE
1
;
Eun Jae CHUNG
;
Seong Keun KWON
Author Information
1. Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Vocal fold paralysis;
Calcium hydroxyapatite;
Injection laryngoplasty
- MeSH:
Acoustics;
Adult;
Asian Continental Ancestry Group;
Calcium;
Durapatite;
Follow-Up Studies;
Humans;
Laryngoplasty;
Male;
Paralysis;
Phonation;
Prospective Studies;
Vocal Cords;
Voice
- From:Journal of the Korean Society of Laryngology Phoniatrics and Logopedics
2018;29(2):83-86
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: This study aimed to evaluate efficacy and complication of injection laryngoplasty using calcium hydroxyapatite (CaHA) for unilateral vocal fold paralysis in Asian. MATERIALS AND METHODS: A prospective study was conducted on the adult patients with unilateral vocal fold paralysis from May 2015 through January 2016. Injection laryngoplasty was performed by one laryngologist. All patients underwent prospective voice evaluation using the subjective and objective comprehensive battery of assessments, before the procedure and after the procedure at 3 months, and 6 months. RESULTS: A total of 7 patients (5 males and 2 females) were included in this study. VHI-10 was significantly decreased after injection laryngoplasty, at postoperative 6 months (p=0.031), while VAS score and MDADI showed no difference. GRBAS scale gradually decreased in 3 months and 6 months follow-up without statistical significance. Acoustic analysis revealed that jitter, shimmer, and noise-to-harmonic ratio continuously decreased from the baseline at 3 months and 6 months, although statistical significance was not attained. In the aerodynamic analysis, maximal phonation time was gradually increased at 3months and 6 months with significant difference (p=0.016, 0.031, respectively). There was no side effect associated with the procedure. CONCLUSION: CaHA can be safely used in Asian patients and the onset of maximal efficacy seems to be slow than other studies with Caucasian patients.
